ASCO 2018: Nivolumab for Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Institution Experience
Chicago, IL (UroToday.com) Nivolumab alone and in combination with ipilimumab are currently FDA approved for patients with metastatic clear cell RCC (MRCC) as 2nd line therapy, and those who are treatment naïve, respectively. Variant histology RCC (VHRCC) to date have very limited therapeutic options and poor outcomes, when compared to clear cell RCC. The role nivolumab in VHRCC is unknown.
ASCO 2018: Effectiveness and Safety of Pazopanib and Everolimus in a Changing Treatment Landscape: Interim Results of the Non-Interventional Study PAZOREAL
Chicago, IL (UroToday.com) Pazopanib, a vascular endothelial growth factor receptor (VEGFR) inhibitor is one of the standard approved treatment options for patients with metastatic renal cell carcinoma (mRCC). One of the potential 2nd line treatment is everolimus, a mammalian target of rapamycin (mTOR) inhibitor. However, in recent years, several additional drugs have been approved for 2nd line treatment. These include the immune checkpoint inhibitors nivolumab (an immune checkpoint [PD-1] inhibitor), and the multikinase inhibitors: cabozantinib and lenvatinib (in combination with everolimus). Because of these newly approved treatments, the therapeutic algorithms for patients with mRCC have considerably changed.
ASCO 2018: Optimization of PD-L1 Algorithm for Predicting OS in Patients with Urothelial Cancer Treated with Durvalumab
Chicago, IL (UroToday.com) Durvalumab is an anti-programmed cell death ligand-1 (PD-L1) immune checkpoint inhibitor that has been tested in patients with advanced urothelial bladder cancer. In a phase I/II open-label study, 191 patients who had progressed on or were ineligible for chemotherapy were administered durvalumab IV 10 mg/kg every two weeks for up to 12 months or until progression or unacceptable side effects . Over a median follow-up was 5.8 months (range, 0.4-25.9), the ORR was 17.8% (95%CI 12.7%-24.0%), including 7 complete responses.
ASCO 2018: Association of Metastasis-Free Survival and Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer
Chicago, IL (UroToday.com) For diseases such as prostate cancer with a relatively long survival, even in advanced stages, survival outcomes (ie. PFS and OS) may take years to occur. The conduct of prostate cancer clinical trials is hampered by taking longer than a decade to reach the meaningful endpoint of OS and the fact that many men never die from prostate cancer, even if they relapse.
ASCO 2018: Precision Active Surveillance: Can Genomic Data Inform Management?
Chicago, IL (UroToday.com) Edward Schaeffer, MD, provided a presentation at the Precision Active Surveillance in Prostate Cancer session, discussing how genomic data can inform further management. Schaeffer started by noting that genomics has transformed our ability to understand malignancies, including prostate cancer, and that select men who appear to be candidates for surveillance harbor genomic alterations consistent with a more aggressive disease.
ASCO 2018: Judicious Use of Therapeutics and Imaging in Early-Stage Prostate Cancer
Chicago, IL (UroToday.com) Following three excellent prostate cancer oral abstracts presented this afternoon at the ASCO 2018, Dr. Felix Feng from UCSF presented an engaging discussion of the implications of the findings presented today.
ASCO 2018: A Randomized Study of Finite Abiraterone Acetate Plus Leuprolide Versus Leuprolide in Biochemically Recurrent Non-Metastatic Hormone Naïve Prostate Cancer
Chicago, IL (UroToday.com) Based on several phase III RCTs published in the last 12 months, we know that abiraterone acetate (AA) improves survival among men with metastatic hormone-naïve prostate cancer [1-2]. Prolonged androgen ablation with sustained ADT has detrimental effects on morbidity and may increase risk of mortality. Several years ago, level 1 evidence was published suggesting that intermittent androgen deprivation is an acceptable treatment option for patients with M0 hormone naïve prostate cancer , with no significant survival difference and improved quality of life versus continuous ADT.